COVID-19
Stephane Bancel, the chief executive of Moderna, has likened the need for booster vaccine doses to the way Apple releases new smartphones every year.
Three studies supporting Merck and Ridgeback Biotherapeutics’ Lagevrio (molnupiravir) will be presented at the ECCMID 2022 in Lisbon from April 23-26.
Two companies in India have halted vaccine manufacturing, which could be a sign that the pandemic may be coming to an end. For that and more COVID-19 news, continue reading.
It was a particularly busy week for clinical trial announcements. Let’s take a look.
The landmark Human Challenge Programme deliberately exposed 36 young and healthy participants ages 18 to 30 with no immunity to the SARS-CoV-2 virus for 14 days.
Although the data suggests the vaccines are extremely effective and generally safe, analysis is still coming in about adverse events as well as effectiveness in specific patient populations.
CAR-T cell therapy is still a time-consuming and expensive process. But researchers may have just solved the turnaround-time challenge for CAR-T.
Researchers have developed a new form of UV light that is safe for people but decreased the level of indoor airborne microbes by more than 98% in less than five minutes.
Although it looks that we’re on the downside of the COVID-19 pandemic in the U.S., biopharma companies are still working on developing better treatments and preventions.
Without holding a meeting of its vaccines advisory committee, the U.S. Food and Drug Administration (FDA) authorized a fourth booster shot for everyone 50 years of age and older.
PRESS RELEASES